Nagi Kumar on Green Tea Catechin Treatment for Prostate Cancer Prevention

Nagi B. Kumar, PhD
Published: Thursday, Jun 18, 2015



Nagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.

Kumar and her team conducted a placebo-controlled, randomized clinical trial of one year of Polyphenon E, a proprietary mixture of green tea catechins in 97 men with high-grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferstion (ASAP) on prostate biopsy. The primary study endpoint was the total number of early organ-confined prostate cancer diagnoses in the PolyE versus placebo arm at one year.

Ten out 26 men in the placebo arm progressed to prostate cancer while only there progressed to prostate cancer in the Polyphenon E arm. The men in the treatment arm also had a significant lowering of PSA throughout the year compared to the placebo arm, says Kumar.



Nagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.

Kumar and her team conducted a placebo-controlled, randomized clinical trial of one year of Polyphenon E, a proprietary mixture of green tea catechins in 97 men with high-grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferstion (ASAP) on prostate biopsy. The primary study endpoint was the total number of early organ-confined prostate cancer diagnoses in the PolyE versus placebo arm at one year.

Ten out 26 men in the placebo arm progressed to prostate cancer while only there progressed to prostate cancer in the Polyphenon E arm. The men in the treatment arm also had a significant lowering of PSA throughout the year compared to the placebo arm, says Kumar.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x